Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens

A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson; Clinical Pharmacogenetics Implementation Consortium (CPIC)

doi:10.1038/clpt.2013.203

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens

Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.

Authors

A J Muir¹, L Gong², S G Johnson³, M T M Lee⁴, M S Williams⁵, T E Klein², K E Caudle⁶, D R Nelson⁷; Clinical Pharmacogenetics Implementation Consortium (CPIC)

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
² Department of Genetics, Stanford University, Palo Alto, California, USA.
³ 1] Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
⁴ 1] Laboratory for International Alliance on Genomic Research, RIKEN Center for Genomic Medicine, Yokohama, Japan [2] National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan [3] School of Chinese Medicine, China Medical University, Taichung, Taiwan.
⁵ Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
⁶ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
⁷ Department of Medicine, University of Florida, Gainesville, Florida, USA.

Abstract

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

Publication types

Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Genetic Testing / standards
Genotype
Hepatitis C / drug therapy*
Humans
Interferon alpha-2
Interferon-alpha / administration & dosage
Interferon-alpha / therapeutic use*
Interferons
Interleukins / genetics*
Polyethylene Glycols / administration & dosage
Polyethylene Glycols / therapeutic use*
Polymorphism, Single Nucleotide / genetics
Recombinant Proteins / administration & dosage
Recombinant Proteins / therapeutic use
Ribavirin / administration & dosage
Ribavirin / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
interferon-lambda, human
Interferon alpha-2
Interferon-alpha
Interleukins
Recombinant Proteins
Polyethylene Glycols
Ribavirin
Interferons
peginterferon alfa-2b
peginterferon alfa-2a

Abstract

Publication types

MeSH terms

Substances

Grants and funding